New drug could simplify bleeding treatment for rare platelet disorder

This lab study tested a new drug called concizumab in blood samples from 20 people with Glanzmann thrombasthenia, a rare genetic bleeding disorder. The drug works by blocking a natural protein that stops clotting, potentially offering a longer-lasting and easier-to-use treatment than current options. The goal was to see if concizumab could improve clot formation in the lab, which could lead to better bleeding control without needing frequent injections.